A Randomized, Double-Blind, Dose-Escalation, Placebo-Controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Subcutaneous Injections of HRS-4729 Injection in Healthy Subjects
Latest Information Update: 28 Jan 2025
Price :
$35 *
At a glance
- Drugs KAI 4729 (Primary) ; Paracetamol
- Indications Obesity; Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Fujian Shengdi Pharmaceutical
- 22 Jan 2025 Status changed from not yet recruiting to recruiting.
- 14 Jan 2025 New trial record